MoonLake Immunotherapeutics (NASDAQ: MLTX) is -26.43% lower on its value in year-to-date trading and has touched a low of $36.52 and a high of $58.26 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MLTX stock was last observed hovering at around $38.39 in the last trading session, with the day’s gains setting it 1.45%.
Currently trading at $39.84, the stock is 1.21% and -5.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing 3.78% at the moment leaves the stock -14.76% off its SMA200. MLTX registered -23.00% loss for a year compared to 6-month loss of -26.58%. The firm has a 50-day simple moving average (SMA 50) of $42.2233 and a 200-day simple moving average (SMA200) of $46.740025.
The stock witnessed a -5.97% gain in the last 1 month and extending the period to 3 months gives it a -23.59%, and is -2.09% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.15% over the week and 4.79% over the month.
MoonLake Immunotherapeutics (MLTX) has around 100 employees, a market worth around $2.55B and $0.00M in sales. Distance from 52-week low is 9.09% and -31.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.53%).
The EPS is expected to shrink by -62.68% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
179.0 institutions hold shares in MoonLake Immunotherapeutics (MLTX), with institutional investors hold 121.71% of the company’s shares. The shares outstanding are 63.08M, and float is at 52.78M with Short Float at 13.72%. Institutions hold 102.88% of the Float.
The top institutional shareholder in the company is BVF INC/IL with over 21.75 million shares valued at $956.4 million. The investor’s holdings represent 34.7258 of the MLTX Shares outstanding. As of 2024-06-30, the second largest holder is CORMORANT ASSET MANAGEMENT, LP with 8.49 million shares valued at $373.49 million to account for 13.5609 of the shares outstanding. The other top investors are FMR LLC which holds 3.64 million shares representing 5.8176 and valued at over $160.23 million, while AVORO CAPITAL ADVISORS LLC holds 4.4223 of the shares totaling 2.77 million with a market value of $121.8 million.
MoonLake Immunotherapeutics (MLTX) Insider Activity
The most recent transaction is an insider sale by BVF PARTNERS L P/IL, the company’s Director. SEC filings show that BVF PARTNERS L P/IL sold 2,000,000 shares of the company’s common stock on Oct 04 ’24 at a price of $50.00 per share for a total of $100.0 million. Following the sale, the insider now owns 1.29 million shares.
MoonLake Immunotherapeutics disclosed in a document filed with the SEC on Oct 04 ’24 that Sturge Simon (Director) sold a total of 171,000 shares of the company’s common stock. The trade occurred on Oct 04 ’24 and was made at $53.72 per share for $9.19 million. Following the transaction, the insider now directly holds 0.17 million shares of the MLTX stock.
